Wedbush Comments on Regulus Therapeutics Inc.’s Q3 2017 Earnings (RGLS)
Regulus Therapeutics Inc. (NASDAQ:RGLS) – Research analysts at Wedbush cut their Q3 2017 earnings estimates for Regulus Therapeutics in a research report issued to clients and investors on Monday. Wedbush analyst L. Moussatos now anticipates that the biopharmaceutical company will earn ($0.14) per share for the quarter, down from their previous estimate of ($0.10). Wedbush currently has a “Ourperform” rating and a $4.00 target price on the stock. Wedbush also issued estimates for Regulus Therapeutics’ Q4 2017 earnings at ($0.13) EPS, FY2017 earnings at ($0.88) EPS, Q2 2018 earnings at ($0.12) EPS, Q3 2018 earnings at ($0.12) EPS, Q4 2018 earnings at ($0.12) EPS, FY2018 earnings at ($0.49) EPS, FY2019 earnings at ($0.52) EPS, FY2020 earnings at ($0.58) EPS and FY2021 earnings at ($0.20) EPS.
Regulus Therapeutics (NASDAQ:RGLS) last posted its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.10. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.02 million. Regulus Therapeutics had a negative net margin of 31,460.47% and a negative return on equity of 173.20%.
A number of other equities research analysts also recently issued reports on RGLS. Needham & Company LLC restated a “hold” rating on shares of Regulus Therapeutics in a report on Wednesday, August 2nd. Chardan Capital cut shares of Regulus Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 2nd. Zacks Investment Research cut shares of Regulus Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. BMO Capital Markets set a $1.00 target price on shares of Regulus Therapeutics and gave the stock a “hold” rating in a research report on Monday, June 12th. Finally, ValuEngine cut shares of Regulus Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. One research analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $3.58.
Regulus Therapeutics (RGLS) opened at 0.9516 on Wednesday. The firm’s market capitalization is $50.61 million. Regulus Therapeutics has a 12-month low of $0.86 and a 12-month high of $3.81. The firm has a 50-day moving average of $1.00 and a 200 day moving average of $1.34.
A number of institutional investors have recently added to or reduced their stakes in the company. Teachers Advisors LLC boosted its stake in shares of Regulus Therapeutics by 15.7% in the fourth quarter. Teachers Advisors LLC now owns 72,273 shares of the biopharmaceutical company’s stock worth $163,000 after buying an additional 9,804 shares during the last quarter. LMR Partners LLP acquired a new stake in Regulus Therapeutics during the second quarter valued at $164,000. Tudor Investment Corp ET AL boosted its stake in Regulus Therapeutics by 131.5% in the first quarter. Tudor Investment Corp ET AL now owns 108,061 shares of the biopharmaceutical company’s stock valued at $178,000 after buying an additional 61,373 shares in the last quarter. Wedbush Securities Inc. boosted its stake in Regulus Therapeutics by 10.3% in the second quarter. Wedbush Securities Inc. now owns 199,521 shares of the biopharmaceutical company’s stock valued at $197,000 after buying an additional 18,600 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its stake in Regulus Therapeutics by 13.5% in the first quarter. Wells Fargo & Company MN now owns 782,380 shares of the biopharmaceutical company’s stock valued at $1,291,000 after buying an additional 93,295 shares in the last quarter. Hedge funds and other institutional investors own 21.09% of the company’s stock.
In other news, Director William H. Rastetter acquired 274,725 shares of the company’s stock in a transaction that occurred on Tuesday, July 25th. The shares were purchased at an average price of $0.91 per share, for a total transaction of $249,999.75. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Joseph P. Hagan acquired 219,780 shares of the company’s stock in a transaction that occurred on Tuesday, July 25th. The stock was purchased at an average price of $0.91 per share, for a total transaction of $199,999.80. Following the acquisition, the insider now directly owns 241,297 shares of the company’s stock, valued at approximately $219,580.27. The disclosure for this purchase can be found here. Insiders have acquired 549,450 shares of company stock valued at $500,000 over the last ninety days. Insiders own 4.80% of the company’s stock.
About Regulus Therapeutics
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.